


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (previously presented): A compound of formula (1) or (2), or a pharmaceutically acceptable salt thereof:



wherein A represents $-S-$;

a, b, c and d are each selected from the group consisting of CR¹ and CR²;

or one of a, b, c and d is N ;

R¹, R² and R⁴ each independently represent H, a halogen, -CF₃, -OR¹⁴, -COR¹⁴, -SR¹⁴, -S(O)_tR¹⁵, -N(R¹⁴)₂, -NO₂, -OC(O)R¹⁴, -CO₂R¹⁴, -OCO₂R¹⁴, -CN, -NR¹⁴COOR¹⁵, -SR¹⁵C(O)OR¹⁵ or -SR¹⁵N(R¹⁶)₂ wherein R¹⁴ represents H, a lower alkyl, an aryl or an aryl-lower alkyl group, R¹⁵ represents a lower alkyl or an aryl group, R¹⁶ is independently selected from the group consisting of H and -C(O)OR¹⁵, and t represents 1 or 2;

R^3 represents H;

V-W represents C=C;

n represents 0 to 3;

R^5 and R^6 each independently represent H, a halogen, $-CF_3$, a lower alkyl or an aryl;
or R^5 and R^6 together form $=O$ or $=S$;

Y^1 represents O or S;

B represents NR^{17a} , $-NR^{17a}(CH_2)_vCHR^{21}-$, $-(CH_2)_vCHR^{21}-$ wherein v represents 0 to 3,
 R^{17a} represents H, a lower alkyl or an aryl, R^{21} represents H, a lower alkyl, an aryl, a
hydroxyl-lower alkyl, $-CH_2SH$, $-CH_2CH_2SCH_3$, $-CH_2(CO)NH_2$, $-CH_2CH_2(CO)NH_2$, $-(CH_2)_w-$
 $COOR^{29}$, $-(CH_2)_w-NR^{29}R^{30}$ wherein R^{29} and R^{30} each independently represent hydrogen atom
or a lower alkyl group, and w represents 0 to 4, $-(CH_2)_3NHC(NH_2)=NH$, benzyl, 4-
hydroxybenzyl, 3-indoymethyl or 5-imidazoymethyl;


G represents $-(CO)-$, $-(SO)-$, $-(SO_2)-$ or a covalent bond;

m represents 0 to 6;

Y^2 represents C or S;

p and q are each independently selected from the group consisting of 1, 2 and 3;

R^7 and R^8 each independently represent H, a lower alkyl, an aryl, $-(CO)R^{18a}$, $-(CS)R^{18a}$, $-(CO)NR^{18a}R^{19a}$, $-(CS)NR^{18a}R^{19a}$ wherein R^{18a} represents H, a lower alkyl, an aryl
or a cycloalkyl group which may have a hetero atom in the ring, R^{19a} represents H, a lower
alkyl or an aryl; or R^{18a} and R^{19a} together form a cycloalkyl which may have a halogen, $-CF_3$,
a lower alkyl or an aryl as a substituent, $-(CO)OR^{20}$ or $-(CS)OR^{20}$ wherein R^{20} represents an
alkyl group having 1 to 12 carbon atoms, an aryl group or a cycloalkyl group which may have
a hetero atom in the ring, or a group of the following general formula (5):



wherein Y^4 and Y^3 each represent O or S; s represents 0 to 6;

E represents NR^{22} or CHR^{23} wherein R^{22} represents H, a lower alkyl or aryl; and R^{23} represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, $-CH_2SH$, $-CH_2CH_2SCH_3$, $-CH_2(CO)NH_2$, $-CH_2CH_2(CO)NH_2$, $-CH_2COOH$, $-CH_2CH_2COOH$, $-(CH_2)_4NH_2$, $-(CH_2)_3NHC(NH_2)=NH$, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl;

R^{24} represents H, a lower alkyl or an aryl;

R^{25} represents H, a lower alkyl, an aryl, $-OR^{18a}$, $-(CO)R^{18a}$, $-(CS)R^{18a}$, $-(CO)NR^{18a}R^{19a}$, $-(CS)NR^{18a}R^{19a}$, $-(CO)OR^{20}$ or $-(CS)OR^{20}$ wherein R^{18a} , R^{19a} and R^{20} are as defined above,

R^9 represents H, a lower alkyl, an aryl, $-(CO)R^{18a}$, $-(CS)R^{18a}$, $-(CO)NR^{18a}R^{19a}$, $-(CS)NR^{18a}R^{19a}$, $-(CO)OR^{20}$ or $-(CS)OR^{20}$ wherein R^{18a} , R^{19a} and R^{20} are as defined above.

Claim 2 (previously presented): A compound or pharmaceutically acceptable salt according to claim 1, wherein:

B represents NR^{17a} , CHR^{21} and CH_2CHR^{21} wherein R^{17a} represents H, a lower alkyl or an aryl, R^{21} represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, $-CH_2SH$, $-CH_2CH_2SCH_3$, $-CH_2(CO)NH_2$, $-CH_2CH_2(CO)NH_2$, $-CH_2COOH$, $-CH_2CH_2COOH$, $-(CH_2)_4NH_2$, $-(CH_2)_3NHC(NH_2)=NH$, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl; and

R^{18a} represents H, a lower alkyl or an aryl, and R^{19a} represents H, a lower alkyl or aryl; or R^{18a} and R^{19a} together form a cycloalkyl group which may have a halogen, $-CF_3$, a lower alkyl or an aryl as a substituent, and R^{25} represents H, a lower alkyl, an aryl, $-(CO)R^{18a}$, $-(CS)R^{18a}$, $-(CO)NR^{18a}R^{19a}$, $-(CS)NR^{18a}R^{19a}$, $-(CO)OR^{20}$ or $-(CS)OR^{20}$.

Claim 3 (previously presented): A compound or pharmaceutically acceptable salt according to claim 2, wherein:

a, b, c and d each represent CH;

R^3 and R^4 each represent hydrogen atom;

R^5 and R^6 each represent hydrogen atom;

or R^5 and R^6 together form $=O$;

n represents 1 or 2;

Y^1 represents O;


B represents NR^{17a} , CHR^{21} - or, CH_2CHR^{21} wherein R^{21} represents H, a lower alkyl, an aryl or $-CH_2OH$;

G represents $-(CO)-$ or a covalent bond;

m represents 0 to 6;

p and q are each 1;

R^7 and R^8 each independently represent H, a lower alkyl, an aryl, $-(CO)R^{18a}$ wherein R^{18a} represents H, a lower alkyl or an aryl, $-(CO)NR^{18a}R^{19a}$ wherein R^{19a} represents H, a lower alkyl or an aryl; or R^{18a} and R^{19a} together form a cycloalkyl which may have a halogen, $-CF_3$, a lower alkyl or an aryl as a substituent, $-(CO)OR^{20}$ wherein R^{20} represents an alkyl group having 1 to 12 carbon atoms, an aryl group or a cycloalkyl group which may contain a hetero atom in the ring, or a group of the following general formula (8):



wherein Y^4 and Y^3 each represent O;

s represents 1 or 2;

E represents CHR^{23} wherein R^{23} represents H,

R^{24} represents H;

R^{25} represents $-(CO)OR^{20}$;

R^9 represents $-(CO)OR^{20}$.

Claim 4 (previously presented): A compound or pharmaceutically acceptable salt according to claim 3, wherein:

a , b , c and d each represent CH;

R^1 and R^2 each represent H;

R^3 and R^4 each represent H;

n represents 2;

R^5 and R^6 each represent H; and

Y^1 represents O.

Claim 5 (previously presented): A compound or pharmaceutically acceptable salt according to claim 1, wherein:

B represents $-(\text{CH}_2)_v-\text{CHR}^{21}$ wherein v represents 2 or 3, R^{21} represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, $-\text{CH}_2\text{SH}$, $-\text{CH}_2\text{CH}_2\text{SCH}_3$, $-\text{CH}_2(\text{CO})\text{NH}_2$, $-\text{CH}_2\text{CH}_2(\text{CO})\text{NH}_2$, benzyl, 4-hydroxybenzyl, 3-indoylmethyl or 5-imidazolymethyl; and R^{18a} represents H, a lower alkyl or an aryl, and R^{19a} represents H, a lower alkyl or aryl; or R^{18a} and R^{19a} together form a cycloalkyl group which may have a halogen, $-\text{CF}_3$, a lower alkyl or an aryl as a substituent.

Claim 6 (previously presented): A compound or pharmaceutically acceptable salt according to claim 5, wherein:

a, b, c and d each represent CH;

R^1 , R^2 , R^3 , R^4 , R^5 and R^6 each represent H;

m represents 0 and n represents 2;


Y^1 represents O[.,.];

G represents a covalent bond[.,.]; and

R^7 and R^8 each independently represent H, a lower alkyl, $-(\text{CO})\text{R}^{18a}$ wherein R^{18a} represents H, a lower alkyl or an aryl, $-(\text{CO})\text{OR}^{20}$ wherein R^{20} represents an alkyl group having 1 to 12 carbon atoms or an aryl.

Claim 7 (canceled).

Claim 8 (previously presented): A compound of formula (1-A), or a pharmaceutically acceptable salt thereof:



wherein A represents -S-;

B represents $-(CH_2)_v-CHR^{21}$ wherein v represents 0 to 3, R^{21} represents H, a lower alkyl, an aryl, a hydroxyl-lower alkyl, $-(CH_2)_w-COOR^{29}$ or $-(CH_2)_w-NR^{29}R^{30}$ wherein R^{29} and R^{30} each independently represent hydrogen atom or a lower alkyl group and w represents 0 to 4;

G represents $-(CO)-$ or a covalent bond;

m represents 0 to 6; and

R^7 and R^8 each independently represent H, a lower alkyl, an aryl, $-(CO)R^{18a}$ wherein R^{18a} represents H, a lower alkyl, an aryl or a cycloalkyl group which may contain a hetero atom in the ring, or $-(CO)OR^{20}$ wherein R^{20} represents an alkyl group having 1 to 12 carbon atoms, an aryl or a cycloalkyl group which may have a hetero atom in the ring.

Claims 9-19 (canceled).

Claim 20 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 1 and at least one pharmaceutically acceptable adjuvant.

Claim 21 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 2 and at least one pharmaceutically acceptable adjuvant.

Claim 22 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 3 and at least one pharmaceutically acceptable adjuvant.


Claim 23 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 4 and at least one pharmaceutically acceptable adjuvant.

Claim 24 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 5 and at least one pharmaceutically acceptable adjuvant.

Claim 25 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 6 and at least one at least one pharmaceutically acceptable adjuvant.


Claim 26 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 8 and at least one pharmaceutically acceptable adjuvant.

Claim 27 (previously presented): A compound having the formula:




or a pharmaceutically acceptable salt thereof.

Claim 28 (previously presented): A compound having the formula:




or a pharmaceutically acceptable salt thereof.

Claim 29 (previously presented): A compound having the formula:



or a pharmaceutically acceptable salt thereof.

Claim 30 (previously presented): A compound having the formula:



or a pharmaceutically acceptable salt thereof.

Claims 31 – 34 (canceled):

Claim 35 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 27 and at least one pharmaceutically acceptable adjuvant.

Claim 36 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 28 and at least one pharmaceutically acceptable adjuvant.

Claim 37 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 29 and at least one pharmaceutically acceptable adjuvant.

Claim 38 (previously presented): A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt according to claim 30 and at least one pharmaceutically acceptable adjuvant.